Tradestie Institutional Equity Comparison Engine
CDT vs IBB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
IBB Overall Edge
IBB Captures Institutional Edge (2โ1 Pillars ยท 3โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to iShares Biotechnology ETF (IBB) driven by superior Momentum & Technical, Options & Structure while CDT counters with relative strength in Growth & Margin. Fundamentally, CDT trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus IBB at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, CDT sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against IBB sits in UNCLASSIFIED (22nd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
CDT N/M vs IBB N/M Fwd P/E
Growth & Margin Winner
CDT
Op Margin 0.0% vs N/A ยท YoY +0.0% vs N/A
Momentum & Technical Winner
IBB
1Y -86.8% vs +20.8% ยท 52W Pos 2% vs 64%
Options & Structure Winner
IBB
BREAKDOWN (N/A IV) vs UNCLASSIFIED (22nd %ile IV)
CDT
NASDAQ
CDT Equity Inc. Common Stock
Pharmaceutical Preparations
$0.23
-13.89% 1D
Market Cap
$507,528
1M Return
+76.79%
1Y Return
-86.78%
Forward P/E
N/M
Unified AI Score
31.6 / 100
SELL
Tech 15.0
Fund 37.0
Flow 50.0
Mom 54.0
IBB
NASDAQ
iShares Biotechnology ETF
Institutional Equity
$199.54
-2.05% 1D
Market Cap
N/A
1M Return
-4.77%
1Y Return
+20.77%
Forward P/E
N/M
Unified AI Score
46.9 / 100
HOLD
Tech 27.0
Fund 47.0
Flow 50.0
Mom 56.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CDT -86.78%
IBB +20.77%
Spread: +107.55 pp (IBB Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CDT TTM Op. Margin: 0.0%
IBB TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CDT vs IBB. Trailing 12-month operating profitability (CDT 0.0% vs IBB N/A) and valuation multiples (CDT N/M vs IBB N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CDT | IBB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $507,528 | N/A | Larger Scale | CDT |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | N/A | Higher Growth | CDT |
| Operating Margin (TTM) Profitability | 0.0% | N/A | Higher Margin | CDT |
| Net Profit Margin Profitability | 0.0% | N/A | Higher Margin | CDT |
| Return on Equity (ROE) Capital Efficiency | -69.7% | N/A | Higher ROE | CDT |
| 52-Week Range Position Momentum | 2% ($0โ$11) | 64% ($160โ$222) | Stronger Trend | IBB |
| Beta / 30D Volatility Risk Regime | -17.75ฮฒ ยท 10175% Vol | 0.84ฮฒ ยท 29% Vol | Lower Realized Risk | IBB |
| Unified Institutional Score Composite Signal | 31.6 / 100 (SELL) | 46.9 / 100 (HOLD) | Higher Composite | IBB |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CDT vs IBB Buy Guide
CDT
BREAKDOWN
163d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
IBB
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
22nd %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CDT nor IBB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.